List of Tables
List of Figures
Introduction
Global Markets Direct Report Coverage
Rosacea - Overview
Rosacea - Therapeutics Development
Pipeline Overview
Pipeline by Companies
Products under Development by Companies
Rosacea - Therapeutics Assessment
Assessment by Target
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Rosacea - Companies Involved in Therapeutics Development
Accuitis Pharmaceuticals Inc
Afecta Pharmaceuticals Inc
Aiviva BioPharma Inc
AlfaSigma SpA
AOBiome LLC
Biomimetix JV LLC
BioPharmX Inc
Botanix Pharmaceuticals Ltd
Cellix Bio Pvt Ltd
Cutanea Life Sciences Inc
Dermata Therapeutics LLC
ELORAC Inc
Emeriti Pharma AB
GlycoMira Therapeutics Inc
Hovione FarmaCiencia SA
Maruho Co Ltd
Matrisys Bioscience Inc
Menlo Therapeutics Inc
Sol-Gel Technologies Ltd
Sunny Pharmtech Inc
Tarsus Pharmaceuticals Inc
TWi Biotechnology Inc
Rosacea - Drug Profiles
AC-701 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
ACUD-1 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
AFX-4031 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
AIV-001 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
B-244 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
benzoyl peroxide - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
BMX-010 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
BPX-04 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
BTX-1702 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
carbamide peroxide - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
CLX-1621 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
CLXDER-621 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
CLXDER-622 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
CLXDER-623 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
DMT-210 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
doxycycline hyclate - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
EP-0003 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
FMX-103 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
GM-0111 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
HY-01 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
M-1220 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
MSB-03 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
omigan pentahydrochloride - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
phenylbutyrate - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
rifaximin DR - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
TP-04 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Rosacea - Dormant Projects
Rosacea - Discontinued Products
Rosacea - Product Development Milestones
Featured News & Press Releases
Feb 18, 2020: Foamix announces integrated efficacy results from the FMX103 1.5% Topical Minocycline Foam Phase 3 program for Rosacea
Feb 13, 2020: Sol-Gel announces positive topline results from open-label, long-term safety study of Epsolay for treatment up to 52 Weeks
Feb 06, 2020: Foamix announces publication of Phase 3 Studies evaluating FMX103 for the treatment of papulopustular rosacea in Jourl of the American Academy of Dermatology
Jan 21, 2020: Sol-Gel announces presentation Epsolay at the 16th Annual Maui Derm for Dermatologists 2020 Meeting
Dec 09, 2019: Botanix initiates BTX 1702 rosacea study
Oct 23, 2019: Foamix enters into manufacturing and supply agreement For FMX103
Oct 17, 2019: Foamix announces FDA acceptance of its New Drug Application for FMX103 Minocycline foam for the treatment of Moderate-to-Severe Papulopustular Rosacea
Oct 16, 2019: Sol-Gel to present on potential of Sol-Gel Microencapsulation Technology in Rosacea at 39th Annual Fall Clinical Dermatology Conference
Oct 10, 2019: Foamix to present data on FMX-103 at 39th Annual Fall Clinical Dermatology Conference
Sep 20, 2019: Hovione announces successful end-of-phase 2 meeting with the FDA and outlines phase 3 program for minocycline topical gel
Aug 06, 2019: Foamix seeks FDA approval for FMX103 to treat rosacea
Jul 08, 2019: Sol-Gel announces positive top-line results from epsolay phase 3 program in papulopustular Rosacea
Jun 26, 2019: BioPharmX reports positive results from BPX-041 trial for rosacea
May 22, 2019: BioPharmX announces last patient visit in Phase 2b trial of BPX-04 for papulopustular rosacea
Mar 04, 2019: BioPharmX completes enrollment in phase 2b trial of BPX-04 for patients with papulopustular rosacea
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer